Scarica l'app Stockscreener
1.37
0.72%
-0.010
Dopo l'orario di chiusura:
1.36
-0.01
-0.73%
Precedente Chiudi:
$1.38
Aprire:
$1.34
Volume 24 ore:
389.30K
Relative Volume:
2.15
Capitalizzazione di mercato:
$57.39M
Reddito:
$9.16M
Utile/perdita netta:
$-68.17M
Rapporto P/E:
-0.8405
EPS:
-1.63
Flusso di cassa netto:
$-80.16M
1 W Prestazione:
+8.73%
1M Prestazione:
+0.00%
6M Prestazione:
-8.67%
1 anno Prestazione:
-17.96%
Intervallo 1D:
$1.30
$1.39
Intervallo di 1 settimana:
$1.20
$1.40
Portata 52W:
$0.9707
$1.94
Ikena Oncology Inc Stock (IKNA) Company Profile
Nome
Ikena Oncology Inc
Settore
Industria
Telefono
857-343-8292
Indirizzo
50 NORTHERN AVE., BOSTON
Confronta IKNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IKNA
Ikena Oncology Inc
|
1.37 | 51.94M | 9.16M | -68.17M | -80.16M | -1.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Ikena Oncology Inc Stock (IKNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-29 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-09-22 | Iniziato | Wedbush | Outperform |
| 2023-05-04 | Ripresa | H.C. Wainwright | Buy |
| 2021-12-23 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-20 | Iniziato | Credit Suisse | Outperform |
| 2021-04-20 | Iniziato | Jefferies | Buy |
| 2021-04-20 | Iniziato | William Blair | Outperform |
Mostra tutto
Ikena Oncology Inc Borsa (IKNA) Ultime notizie
What analysts say about Ikena Oncology Inc. stockHigh-impact stock picks - PrintWeekIndia
Ikena Oncology, Inc. SEC 10-Q Report - TradingView
Ikena Oncology shares climb as Kristin Yarema named CEO of soon-to-merge ImageneBio - MSN
Ikena Oncology to implement 1-for-12 reverse stock split and rebrand as ImageneBio By Investing.com - Investing.com South Africa
Ikena Oncology Announces Reverse Stock Split and Rebrand - TipRanks
Ikena to Rebrand as ImageneBio, Start 1-for-12 Reverse Split 28 Jul 2025 | IKNA SEC FilingForm 8-K - Stock Titan
Ikena Oncology and Inmagene Biopharmaceuticals Announce - GlobeNewswire
Kristin Yarema to lead merged Inmagene-Ikena entity - BioCentury
Ikena Oncology stock rises after naming Kristin Yarema as CEO of combined company - Investing.com India
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company - The Manila Times
Ikena Oncology and Inmagene name Kristin Yarema as CEO of combined firm By Investing.com - Investing.com South Africa
Roche-Acquired Poseida CEO Takes Helm at Ikena-Inmagene Merger with $75M Funding - Stock Titan
Ikena Oncology Inc. Stock Analysis and ForecastRemarkable growth - Autocar Professional
Ikena Oncology Announces Merger with Inmagene - TipRanks
IKNA issues special CVR dividend ahead of Inmagene merger | IKNA SEC FilingForm 8-K - Stock Titan
What drives Ikena Oncology Inc. stock priceBreakneck growth rates - jammulinksnews.com
Is Ikena Oncology Inc. a good long term investmentBreakthrough stock performance - jammulinksnews.com
Ikena Oncology Approves Merger and Reverse Stock Split - The Globe and Mail
Ikena Oncology amends executive agreement with Dr. Jotin Marango for equity vesting - Investing.com Nigeria
Ikena Oncology amends executive agreement with Dr. Jotin Marango for equity vesting By Investing.com - Investing.com South Africa
Ikena Oncology Updates Employment Terms Amid Merger Plans - TipRanks
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals - GlobeNewswire
How Ikena Oncology Inc. stock performs during market volatilityIntraday Trade Ideas - Newser
Ikena Oncology announces stockholder approval of merger with Inmagene Biopharmaceuticals - MarketScreener
Ikena shareholders approve merger with Inmagene, reverse stock split - Investing.com Australia
Ikena announces 1-for-12 reverse stock split, approval of Inmagene merger - TipRanks
Ikena shareholders approve merger with Inmagene, reverse stock split By Investing.com - Investing.com Nigeria
Ikena Oncology Approves Merger with Inmagene Biopharmaceuticals - AInvest
Ikena Oncology Shareholders Green Light Inmagene Merger: What the 1-for-12 Split Means for Investors - Stock Titan
Why Ikena Oncology Inc. stock attracts strong analyst attentionFree Best Performing Stock Alerts - Newser
What makes Ikena Oncology Inc. stock price move sharplyFree Stock Market Real-Time Monitoring - Newser
Ikena Oncology Merger Recommended by Shareholder Services - The Globe and Mail
SBET spends $25.7M on 10,000 ETH; Share-reserve waiver opens ATM issuances | IKNA SEC FilingForm 8-K - Stock Titan
Ikena Oncology Announces Support from ISS and Glass Lewis for Shareholder Vote on Inmagene Merger - Nasdaq
Ikena Oncology Announces ISS and Glass Lewis Recommend - GlobeNewswire
Ikena Oncology (NASDAQ:IKNA) Stock Price Up 1.5% – Here’s Why - Defense World
Ikena Oncology Inc Azioni (IKNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):